Non–Small-Cell Lung Cancer
Specialty Channel

Featured Article
Among patients with NSCLC, first-line nivolumab plus ipilimumab combined with chemo yields greater OS than chemo alone.
The FDA has approved tepotinib for the treatment of adults with metastatic NSCLC with MET exon 14 skipping alterations.
True or false: Platinum-based chemotherapy demonstrated a longer overall survival than atezolizumab in NSCLC patients with high PD-L1 expression.
First-line lorlatinib, when compared to crizotinib, demonstrated longer PFS and a higher frequency of intracranial response in previously treated patients with ALK-positive NSCLC.
Multimodality therapy demonstrated higher OS when combined with neoadjuvant therapy in patients with stage IIB NSCLC.
Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020…
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Jonathan Goldman, MD, provided an overview of how to manage patients with ALK-resistance in non-small-cell lung cancer (NSCLC).
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Alexander Drilon PhD, Memorial Sloan Kettering Cancer Center, New York, shared insight on MET-dependent…
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.

News

Among patients with NSCLC, first-line nivolumab plus ipilimumab combined with chemo yields greater OS than chemo alone.
The FDA has approved tepotinib for the treatment of adults with metastatic NSCLC with MET exon 14 skipping alterations.
First-line lorlatinib, when compared to crizotinib, demonstrated longer PFS and a higher frequency of intracranial response in previously treated patients with ALK-positive NSCLC.
Multimodality therapy demonstrated higher OS when combined with neoadjuvant therapy in patients with stage IIB NSCLC.

Interactive Features

True or false: Platinum-based chemotherapy demonstrated a longer overall survival than atezolizumab in NSCLC patients with high PD-L1 expression.
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.
True or false: Tepotinib therapy initiated a complete response in approximately 60% of patients with advanced NSCLC and MET exon 14 skipping mutation, in a recent trial.
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
Stay in the know.
OncNet Newsletter